Drugs / BCG
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06833073 Background | Mar 2025 → Sep 2031 expected | in situ carcinoma, urinary bladder neoplasm | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06833073 ↗ |
| Route | Other | “Intravesicular instillation.” NCT06833073 ↗ |